NCT06983210 2025-08-14
GRAPE
Nagoya University
Phase 2 Recruiting
Clinical Trials
8 trialsNCT04905407 2025-02-24
Tamibarotene Plus Venetoclax/Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
Syros Pharmaceuticals
Phase 2 Terminated
NCT02807558 2024-12-13
A Biomarker-Directed Phase 2 Trial of Tamibarotene (SY-1425) in Participants With Acute Myeloid Leukemia or Myelodysplastic Syndrome
Syros Pharmaceuticals
Phase 2 Completed
NCT05064618 2024-04-04
MIKE-1
Nagoya University
Phase 1/2 Recruiting
NCT06085638 2024-03-07
Phase I/II Study of SY-1425 (Tamibarotene) in Combination With Azacitidine and Venetoclax for Patients With Chronic Myelomonocytic Leukemia
M.D. Anderson Cancer Center
Phase 1/2 Withdrawn
NCT00985530 2013-10-30
Tamibarotene and Arsenic Trioxide for Relapsed Acute Promyelocytic Leukemia
Northwestern University
Phase 1 Terminated
NCT01337154 2013-06-28
First Line Study of Tamibarotene in Combination for Advanced Non-Small Cell Lung Cancer
CytRx
Phase 2 Terminated
NCT00520208 2013-02-13
STAR-1
CytRx
Phase 2 Completed